Pittman PR, Sjogren MH, Hack D, Franz D, Makuch RS, Arthur JS. 1997. Serologic Response to Anthrax and Botulinum Vaccines. Protocol No. FY92-5, M109, Log No. A-5747. Final report to the Food and Drug Administration. Fort Detrick, Md.: U.S. Army Medical Research Institute of Infectious Diseases.

Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, Friedlander AM. 2000. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19(2–3):213–216.

Pittman PR, Kim-Ahn G, Pifat DY, Coon K, Gibbs P, Little S, Pace-Templeton J, Myers R, Parker GW, Friedlander AM. 2002. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Vaccine 20(9–10):1412–1420.

Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT, Jr, Friedlander AM, Sjogren MH. In press. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine.

Plotkin SA, Brachman PS, Utell M, Bumford FH, Atchison MM. 1960. An epidemic of inhalation anthrax, the first in the twentieth century. American Journal of Medicine 29:992– 1001.

Pomerantsev AP, Staritsin NA, Mockov YuV, Marinin LI. 1997. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15(17–18):1846–1850.

Price LB, Hugh-Jones M, Jackson PJ, Keim P. 1999. Genetic diversity in the protective antigen gene of Bacillus anthracis. Journal of Bacteriology 181(8):2358–2362.

Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A, Velan B. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infection and Immunity 69(5):2888–2893.

Ross JM. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. Journal of Pathology and Bacteriology 73:485–494.

Sellman BR, Mourez M, Collier RJ. 2001. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292(5517):695–697.

Smith H, Keppie J. 1954. Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature 173:869.

Suffin SC, Carnes WH, Kaufmann AF. 1978. Inhalation anthrax in a home craftsman. Human Pathology 9(5):594–597.

Turnbull PC. 1991. Anthrax vaccines: past, present and future. Vaccine 9(8):533–539.

Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infection and Immunity 52(2):356–363.

Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Medical Microbiology and Immunology 177(5):293–303.

Walker D. 2001. Quantitative pathology of inhalational anthrax. Presentation to the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Meeting III, Washington, D.C.

Welkos SL. 1991. Plasmid-associated virulence factors of non-toxigenic (pX01) Bacillus anthracis. Microbial Pathogenesis 10(3):183–198.

Welkos SL, Friedlander AM. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microbial Pathogenesis 5(2):127–139.

Welkos S, Becker D, Friedlander A, Trotter R. 1990. Pathogenesis and host resistance to Bacillus anthracis: a mouse model. Salisbury Medical Bulletin 63(Suppl):49–52.

Welkos SL, Vietri NJ, Gibbs PH. 1993. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microbial Pathogenesis 14(5):381–388.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement